483 Roundup: Sterile Conditions Elude Drug Producers, FDA Says

Drug GMP Report
A A
Shortcomings in sterile drug processing landed three companies in trouble with the FDA, while a fourth was chastised for neglect of a customer’s complaint, as reflected in Form 483 inspection reports.

To View This Article:

Login

Subscribe To Drug GMP Report